FLNANasdaqPharmaceutical PreparationsFiscal year ends December 31
FILANA THERAPEUTICS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$0.68−0.02 (-3.06%)
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2011 to 2025
Operating margin
–
Net margin
–
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2016 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | -61.9% | -11.1% | -82.7% | |
| Return on assets | -58.0% | -10.8% | -65.9% | |
| Current ratio | 28.68 | 50.40 | 2.23 | |
| Diluted shares | 7M | 26M | 48M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Filana Therapeutics generated $338.92M from operations and spent $26.02M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$338.92M
Used
$26.02M
Capital expenditure$26.02M100%Dividends$00%Share buybacks$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
1of 6 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$90.97M
- Cash generatingOperating cash flow above zero-$32.25M
- Return on assets improvedROA up on the prior year-16.1% → -57.7%
- Earnings backed by cashOperating cash flow above net income-$32.25M vs -$90.97M
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose11.62 → 2.23
- No dilutionShare count did not rise47M → 48M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –